Additionally, in patients with PDA, anti-CD40 therapy is associated with depletion and activation of B cells (25, 26), However, beyond B cell pharmacodynamics, there is limited understanding of the cellular response to a CD40 agonist in patients with PDA. This evidence concerns the gene CD40 and Patent ductus arteriosus.